Hong Kong vs South-East Asia (WHO region): Treatment success rate: XDR-TB cases
Hong Kong
100
in 2022
South-East Asia (WHO region)
73
in 2022
Hong Kong rank
1st
South-East Asia (WHO region) rank
2nd
Treatment success rate: XDR-TB cases over time
- Hong Kong
- South-East Asia (WHO region)
How they compare
Hong Kong currently reports 100 against 73 in South-East Asia (WHO region), a difference of 27.
That makes Hong Kong's figure about 1.4 times South-East Asia (WHO region)'s.
The two have swapped places 4 times across 11 shared years of data; in 2011 it was Hong Kong ahead.
Hong Kong ranks 1st and South-East Asia (WHO region) ranks 2nd of 82 countries.
Hong Kong has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Hong Kong | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 81.25 | 36.75 | 44.5 | Hong Kong |
| 2020s | 89 | 69 | 20 | Hong Kong |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate: xdr-tb cases, Hong Kong or South-East Asia (WHO region)?
- Hong Kong, at 100 against 73 in South-East Asia (WHO region) as of 2022.
- What is the difference in treatment success rate: xdr-tb cases between Hong Kong and South-East Asia (WHO region)?
- 27, with Hong Kong ahead.
- How many years of comparable data are there for Hong Kong and South-East Asia (WHO region)?
- 11 years are reported by both, from 2011 to 2022.
- How do Hong Kong and South-East Asia (WHO region) rank globally for treatment success rate: xdr-tb cases?
- Hong Kong ranks 1st and South-East Asia (WHO region) ranks 2nd of 82 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate: XDR-TB cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.